95 Cancer treatment remains a daily reality for millions of people, often involving therapies that are effective but physically demanding and difficult to tolerate. Researchers are increasingly looking for approaches that can attack tumours more precisely while limiting harm to healthy tissue. One emerging area of interest is the use of carbon nanozymes, a class of engineered nanomaterials designed to mimic the behaviour of natural enzymes inside the body. The findings were published in Biomaterials. Carbon nanozymes are tiny particles made primarily from carbon based materials, measured on a scale thousands of times smaller than the width of a human hair. Unlike natural enzymes, which can be fragile and expensive to produce, these synthetic alternatives are more stable and easier to manufacture. Their durability means they can function in harsh biological environments where traditional treatments often struggle. At the heart of their appeal is their ability to trigger chemical reactions inside tumours. Many carbon nanozymes can convert substances already present in cancer cells into highly reactive molecules that damage cancer tissue from within. These reactions increase oxidative stress in tumours, disrupting cellular processes and leading to cell death. Importantly, this effect tends to be stronger in cancer cells than in normal tissue, offering a degree of selectivity that is difficult to achieve with conventional chemotherapy. The review highlights how different forms of carbon nanozymes can be tailored for specific roles. Some are engineered to generate toxic oxygen based molecules directly inside tumours. Others are designed to release oxygen in low oxygen tumour environments, a key limitation that reduces the effectiveness of radiotherapy and phototherapy. By improving oxygen availability, these nanozymes can make existing cancer treatments work more effectively. Another advantage lies in versatility. Carbon nanozymes can be combined with established therapies such as chemotherapy, immunotherapy, and heat-based treatments. This multi approach strategy allows researchers to attack cancer on several fronts at once, potentially reducing the likelihood of resistance and recurrence. In laboratory and animal studies, these combined methods have shown stronger tumour suppression than single treatments alone. Safety is also a central concern. Carbon based materials are generally well tolerated by the body and can be modified to improve compatibility and targeting. The review notes that many carbon nanozymes show low toxicity in preclinical studies, with minimal damage to surrounding healthy tissue. Their surfaces can also be adapted to recognise tumour specific features, improving precision and reducing unwanted side effects. Despite the promise, the research remains largely at an experimental stage. Most evidence so far comes from laboratory models rather than human trials. Questions remain around long term safety, large scale production, and how these materials behave over time inside the body. Translating these findings into approved clinical treatments will require careful testing and regulatory scrutiny. Still, the direction of travel is clear. Carbon nanozymes offer a flexible platform that bridges chemistry, nanotechnology, and medicine. By exploiting the unique weaknesses of cancer cells, they may help reshape how cancer is treated in the future, moving towards therapies that are not only effective but also kinder to patients.